Oral Semaglutide was approved by the FDA in September 2019 to improve blood glucose control in adult patients with type 2 diabetes (1). Semaglutide is a GLP-1 receptor agonist that stimulates the β-cells in the pancreas for insulin secretion, suppresses glucagon secretion from pancreatic α-cells, and delays gastric emptying. It is the first GLP-1 receptor agonist formulated for oral administration. An absorption enhancement known as sodium N-(8-[2-hydroxylbenzoyl] amino) cap